CLINICAL TRIALS PROFILE FOR ZEPATIER
✉ Email this page to a colleague
All Clinical Trials for ZEPATIER
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02743897 ↗ | Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients | Active, not recruiting | Merck Sharp & Dohme Corp. | Phase 1/Phase 2 | 2016-05-01 | This study is being conducted to determine safety and effectiveness of transplanting kidneys from Hepatitis C-positive donors into Hepatitis C-negative patients on the kidney transplant waitlist, who will then be treated with the appropriate direct-acting antiviral (DAA) after the single kidney transplantation. |
| NCT02743897 ↗ | Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients | Active, not recruiting | University of Pennsylvania | Phase 1/Phase 2 | 2016-05-01 | This study is being conducted to determine safety and effectiveness of transplanting kidneys from Hepatitis C-positive donors into Hepatitis C-negative patients on the kidney transplant waitlist, who will then be treated with the appropriate direct-acting antiviral (DAA) after the single kidney transplantation. |
| NCT02781649 ↗ | Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2016-07-20 | In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include Grazoprevir (GZR) 100 mg/Elbasvir (EBR) 50 mg administered on-call to the operating room for the renal transplant procedure and continued for 12 weeks post-renal transplant. |
| NCT02781649 ↗ | Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients | Completed | Johns Hopkins University | Phase 4 | 2016-07-20 | In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include Grazoprevir (GZR) 100 mg/Elbasvir (EBR) 50 mg administered on-call to the operating room for the renal transplant procedure and continued for 12 weeks post-renal transplant. |
| NCT02786537 ↗ | Study of Oral Treatments for Hepatitis C | Completed | AbbVie | Phase 4 | 2016-06-01 | Phase 1 of this study compared the effectiveness of 3 approved DAA (direct-acting antiviral) HCV treatment regimens to learn whether they worked equally well under real-world conditions. Phase 2 of this study began early 2017 with removal of 1 DAA regimen, limiting randomization to just 2 FDA approved DAA regimens. Patients receiving HCV therapy in community and academic clinics were offered the opportunity to consent to be randomly assigned to one of three (phase 1) or one of two (phase 2) regimens and observed for outcomes. Once randomized, all medical care, laboratory testing, and any disease or side effect management were assumed by usual care conditions, and patient-reported outcomes were collected outside clinic in keeping with pragmatic design principles. |
| NCT02786537 ↗ | Study of Oral Treatments for Hepatitis C | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2016-06-01 | Phase 1 of this study compared the effectiveness of 3 approved DAA (direct-acting antiviral) HCV treatment regimens to learn whether they worked equally well under real-world conditions. Phase 2 of this study began early 2017 with removal of 1 DAA regimen, limiting randomization to just 2 FDA approved DAA regimens. Patients receiving HCV therapy in community and academic clinics were offered the opportunity to consent to be randomly assigned to one of three (phase 1) or one of two (phase 2) regimens and observed for outcomes. Once randomized, all medical care, laboratory testing, and any disease or side effect management were assumed by usual care conditions, and patient-reported outcomes were collected outside clinic in keeping with pragmatic design principles. |
| NCT02786537 ↗ | Study of Oral Treatments for Hepatitis C | Completed | Patient-Centered Outcomes Research Institute | Phase 4 | 2016-06-01 | Phase 1 of this study compared the effectiveness of 3 approved DAA (direct-acting antiviral) HCV treatment regimens to learn whether they worked equally well under real-world conditions. Phase 2 of this study began early 2017 with removal of 1 DAA regimen, limiting randomization to just 2 FDA approved DAA regimens. Patients receiving HCV therapy in community and academic clinics were offered the opportunity to consent to be randomly assigned to one of three (phase 1) or one of two (phase 2) regimens and observed for outcomes. Once randomized, all medical care, laboratory testing, and any disease or side effect management were assumed by usual care conditions, and patient-reported outcomes were collected outside clinic in keeping with pragmatic design principles. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ZEPATIER
Condition Name
Clinical Trial Locations for ZEPATIER
Trials by Country
Clinical Trial Progress for ZEPATIER
Clinical Trial Phase
Clinical Trial Sponsors for ZEPATIER
Sponsor Name
